0.790
-0.03 (-3.66%)
| Penutupan Terdahulu | 0.820 |
| Jumlah Dagangan | 11,693 |
| Harga / Buku (P/B) | 0.570 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -13.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 30.79% |
| Nisbah Semasa (MRQ) | 4.30 |
| Aliran Tunai Operasi (OCF TTM) | -19.35 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.68 M |
| Pulangan Atas Aset (ROA TTM) | -73.25% |
| Pulangan Atas Ekuiti (ROE TTM) | -174.66% |
AISkor Stockmoo
| Nilai 30% | -0.6 |
| Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info | |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | -4.4 |
| Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga turun. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Pegangan info | NA |
| Sentimen Berita info | NA |
| Wang Pintar 20% | -1.4 |
| Institusi bersih -1.84% daripada saham dalam pemfailan 13F terkini: 5 pemegang menambah, 9 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -82.7% dari 31 Aug hingga 30 Oct 2026, 1 hari untuk tutup (FINRA). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Di bawah garis aliran jangka sederhana. info | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Paras sokongan dan rintangan menurun. info | |
| Skor Akhir | -2.52 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | IN8bio, Inc. | Bercampur | Bercampur |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| INAB | - | - | - | 0.570 | -2.5 |
| HLVX | 103 M | - | - | 0.710 | 0.0 |
| MEIP | 49 M | - | - | - | 0.0 |
| SONN | 33 M | - | - | 2.07 | -1.4 |
| ANIX | - | - | - | 6.26 | -1.6 |
| PLRX | - | - | - | 0.320 | -3.8 |
|
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.20% |
| % Dimiliki oleh Institusi | 20.95% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Texas Capital Bank Wealth Management Services Inc | 30 Sep 2026 | 23,521 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 34.95%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 5 | 72,270 |
| Berkurang | 9 | 189,613 |
| Baharu | 2 | 10,936 |
| Dijual habis | 2 | 96,337 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 15,733 | 1.0 |
| 15 Oct 2026 | 32,797 | 1.0 |
| 30 Sep 2026 | 46,440 | 1.0 |
| 15 Sep 2026 | 63,110 | 2.2 |
| 31 Aug 2026 | 90,842 | 1.6 |
| 14 Aug 2026 | 139,903 | 1.4 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
Median overall survival (mOS) of 20.9 months in repeat-dose patients, compared to 13.2 months (+59%) in the group receiving standard-of-care (SOC) 50% of repeat-dose patients remained alive at two years, compared to 10% in the SOC control group Median progression-free survival (mPFS) of 13.0… |
| 06 Nov 2026 | Yahoo Finance |
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the… |
| 05 Nov 2026 | Yahoo Finance |
IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & DevelopmentReceived third-party recognition of INB-619 in a Nature Reviews Drug Discovery review of next-generation immune cell engagers for autoimmune diseaseRemain… |
| 22 Sep 2026 | Yahoo Finance |
IN8bio to Present at Sidoti Small-Cap Virtual Conference
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and… |
| 10 Sep 2026 | Yahoo Finance |
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that William Ho, Chief Executive Officer and… |
| 09 Sep 2026 | Yahoo Finance |
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
Headshot Oxana Polyakova, Ph.D., Senior Vice President of Research & Development, IN8bio Renowned γδ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio’s leadership and domain expertise as they advance… |
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |